Cryosurgical ablation of unresectable hepatic metastases

Abstract

Background and Objectives: Recent advancements in the technology of cryosurgery along with the development and refinement of intraoperative ultrasound have led to a feasible alternative for some patients with unresectable hepatic malignancy. This paper reports our first year's experience with cryosurgical ablation of unresectable hepatic malignancies. Methods From May 1996 to July 1997, 12 patients with colorectal hepatic metastases underwent exploration for possible resection and/or cryosurgery. At surgery, three patients had extensive disease and were not candidates for any surgical treatment, three underwent formal right hepatic lobectomy, five underwent a combination of resection and cryoablation, while one underwent cryoablation alone. Results In the six patients who received cryosurgery, the mean number of metastatic lesions was four (range 1–6). The mean number of lesions frozen was two (range 1–4) with a mean size of 2.5 cm. (range 1–5 cm). There were no intraoperative deaths and no major postoperative complications. All patients were discharged home in stable condition with a mean hospital stay of eight days (range 5–14 days). At a mean follow‐up of 17.3 months (range 10–22) three patients were alive with disease and three were disease free. Conclusions Cryosurgical ablation is a safe method of treating unresectable hepatic malignancies and it may extend survival in carefully selected patients. J. Surg. Oncol. 68:242–245, 1998. © 1998 Wiley‐Liss, Inc.

Polymer Implants for Intratumoral Drug Delivery and Cancer Therapy

“…Image‐guided, minimally invasive techniques for therapeutic interventions use regional tumor destruction as an alternative to surgical resection 10. Strategies for tumor ablation include thermal heating,11, 12 cryosurgery,13, 14 or chemical ablation 15, 16. In each of these techniques, an interventional needle or electrode is inserted into the tumor with image guidance 17, 18.…”

Cancer du sein en situation métastatique

“…Deux autres publications coréennes en 2009 retrouvent des taux de récidive ganglionnaire après GS négatif de 2,1 % (29/1817) et 1,02 % (3/720) avec des suivis de 24 mois et 40 mois respectivement (62,63).…”

“…Le gros calibre des sondes de cryothérapie explique que cette technique est peu utilisée en percutané. La morbidité de cette technique est faible et la survie moyenne semble bonne (63,132,174,236,258,284). Steele et al (258) ont confirmé, par étude histologique, la destruction tissulaire tumorale après cryothérapie.…”

Cancer du sein métastatique

“…Le gros calibre des sondes de cryothé rapie explique que cette technique est peu utilisé e en percutané . La morbidité de cette technique est faible, et la survie moyenne semble bonne [64,136,175,238,287]. Steele et al [260] ont confirmé , par é tude histologique, la destruction tissulaire tumorale aprè s cryothé rapie.…”